Introduction: There is continuous experience that AKI is very common in COVID-19 patients and that SARS-CoV-2 specifically invades the kidneys with poor outcome. In-hospital AKI is associated with multiple risk factors including DM, CCF, drugs etc. Also, there is difference in the mortality rate all over the world for various reasons. To date no data has been found from Pakistan on outcome of AKI with COVID-19 infection. Therefore, this study was conducted to help determine the outcome and associated risk factors in this part of the world.
Material and Method: This is a prospective cohort of COVID-19 adult patients with AKI admitted in Indus Hospital COVID ICU from March 2020 to September 2020. History, clinical examination, laboratory investigations, and ultrasound imaging of the kidneys was acquired from the Health Management Information System (HMIS) record of the patients. The data was analyzed in SPSS version 21. Association between outcomes of AKI with different variables was assessed by applying Chi square test. P value of less than 0.05 was considered significant.
Results: There were total 208 patients with AKI in our study, in which 146 (70.2%) were male while 62(29.8%) were female. The mean age was 60.3± 12.7 years and the most prevalent comorbid was HTN 147(70.7%) in our patients, while the most common cause of AKI was sepsis 188(90.4%) and on the same way, oliguria was the most common symptoms of AKI 76(36.5%). Death was the most frequent outcome of our patients 147(70.7%) as compared to recovery 47(22.6%). There was male predominance in patients, who died with AKI as compared to female 112(76.2%) and 35(23.8%) respectively. Also, treatment didn’t show any benefit on worst outcome. Similarly, 124(59.6%) patients needed ventilatory support in which 118(95.2%) died while only 5 (4%) recovered (p <0.001)
Conclusion: Renal involvement in SARS-COV-2 infection is more common than initially thought and has been associated with increased morbidity and mortality. We have found significant association of AKI in covid-19 with outcome variables.
Peerapornratana S, Manrique-Caballero CL, Gomez H, Kellum JA. Acute kidney injury from sepsis: current concepts, epidemiology, pathophysiology, prevention and treatment. Kidney international. 2019 Nov 1;96(5):1083-99.
Arentz M, Yim E, Klaff L. Characteristics and outcomes of 21 critically ill patients with COVID-19 in Washington state [published online March 19, 2020]. JAMA. doi.;10.
Wang L, Li X, Chen H, Yan S, Li D, Li Y, Gong Z. Coronavirus disease 19 infection does not result in acute kidney injury: an analysis of 116 hospitalized patients from Wuhan, China. American journal of nephrology. 2020;51(5):343-8.
Bhatraju PK, Ghassemieh BJ, Nichols M, Kim R, Jerome KR, Nalla AK, Greninger AL, Pipavath S, Wurfel MM, Evans L, Kritek PA. Covid-19 in critically ill patients in the Seattle region—case series. New England Journal of Medicine. 2020 May 21;382(21):2012-22.
Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, Liu L, Shan H, Lei CL, Hui DS, Du B. Clinical characteristics of coronavirus disease 2019 in China. New England journal of medicine. 2020 Apr 30;382(18):1708-20.
Grasselli G, Zangrillo A, Zanella A, Antonelli M, Cabrini L, Castelli A. Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy. Jama [Internet]. 2020; 1–8.
Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, Davidson KW, Barnaby DP, Becker LB, Chelico JD, Cohen SL, Cookingham J. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area. Jama. 2020 Apr 22.
covid19.who.int/coronavirus/world dashboard noted on 1-11-2020.
Pei G, Zhang Z, Peng J, Liu L, Zhang C, Yu C, Ma Z, Huang Y, Liu W, Yao Y, Zeng R. Renal involvement and early prognosis in patients with COVID-19 pneumonia. Journal of the American Society of Nephrology. 2020 Jun 1;31(6):1157-65.
Zahid U, Ramachandran P, Spitalewitz S, Alasadi L, Chakraborti A, Azhar M, Mikhalina G, Sherazi A, Narh JT, Khattar P, Bedi P. Acute kidney injury in COVID-19 patients: An inner city hospital experience and policy implications. American Journal of Nephrology. 2020;51(10):786-96.
Hirsch, J. S. et al. Acute kidney injury in patients hospitalized with COVID-19. Kidney Int. 98, 209–218 (2020)
Mohamed MM, Lukitsch I, Torres-Ortiz AE, Walker JB, Varghese V, Hernandez-Arroyo CF, Alqudsi M, LeDoux JR, Velez JC. Acute kidney injury associated with coronavirus disease 2019 in urban New Orleans [published online ahead of print May 13, 2020]. Kidney360 doi.;10.
Cheng Y, Luo R, Wang X, Wang K, Zhang N, Zhang M, Wang Z, Dong L, Li J, Zeng R, Yao Y. The incidence, risk factors, and prognosis of acute kidney injury in adult patients with coronavirus disease 2019. Clinical Journal of the American Society of Nephrology. 2020 Oct 7;15(10):1394-402.
Robbins-Juarez SY, Qian L, King KL, Stevens JS, Husain SA, Radhakrishnan J, Mohan S. Outcomes for Patients With COVID-19 and acute kidney injury: a systematic review and meta-analysis. Kidney International Reports. 2020 Aug 1;5(8):1149-60.
Atif M, Malik I. Why is Pakistan vulnerable to COVID‐19 associated morbidity and mortality? A scoping review. The International journal of health planning and management. 2020 Sep;35(5):1041-54.
Saeed Shah. Why Youthful, Conservative Pakistan Is a Coronavirus Bright. Spot.www.wsj.com . august 1, 2020.
Yamamoto N, Bauer G. Apparent difference in fatalities between Central Europe and East Asia due to SARS-COV-2 and COVID-19: Four hypotheses for possible explanation. Medical hypotheses. 2020 Nov 1;144:110160.
Yanez ND, Weiss NS, Romand JA, Treggiari MM. COVID-19 mortality risk for older men and women. BMC Public Health. 2020 Dec;20(1):1-7.
The Sex, Gender, and COVID-19 Project. The COVID-10 sex-disaggregated data tracker. https://globalhealth5050.org/covid19/ (accessed December 6, 2020).
Shibata S, Arima H, Asayama K, Hoshide S, Ichihara A, Ishimitsu T, Kario K, Kishi T, Mogi M, Nishiyama A, Ohishi M. Hypertension and related diseases in the era of COVID-19: a report from the Japanese Society of Hypertension Task Force on COVID-19. Hypertension Research. 2020 Oct;43(10):1028-46.
Cheng Y, Luo R, Wang K, Zhang M, Wang Z, Dong L, Li J, Yao Y, Ge S, Xu G. Kidney impairment is associated with in-hospital death of COVID-19 patients. MedRxiv. 2020 Jan 1.
Hirsch JS, Ng JH, Ross DW, Sharma P, Shah HH, Barnett RL, et al. Acute kidney injury in patients hospitalized with Covid-19. Kidney Int. 2020. Epub 2020 May 18. https://doi.org/10.1016/j.kint.2020.05.006 PMID: 32416116.
Kolhe NV, Fluck RJ, Selby NM, Taal MW. Acute kidney injury associated with COVID-19: A retrospective cohort study. PLoS medicine. 2020 Oct 30;17(10):e1003406.
Huang L, Xue C, Kuai J, Ruan M, Yang B, Chen X, Zhang Y, Qian Y, Wu J, Zhao X, Mei C. Clinical Characteristics and Outcomes of Community-Acquired versus Hospital-Acquired Acute Kidney Injury: A Meta-Analysis. Kidney and Blood Pressure Research. 2019;44(5):879-96.
Chen Z, Zhang F, Hu W, Chen Q, Li C, Wu L, Zhang Z, Li B, Ye Q, Mei J, Yue J. Laboratory markers associated with COVID‐19 progression in patients with or without comorbidity: A retrospective study. Journal of clinical laboratory analysis. 2020 Oct 28:e23644.
Zhu HM, Li Y, Li BY, Yang S, Peng D, Yang X, Sun XL, Zhang M. Effect of methylprednisolone in severe and critical COVID-19: Analysis of 102 cases. World Journal of Clinical Cases. 2020 Dec 6;8(23):5952.
Madsen LW. Remdesivir for the Treatment of Covid-19-Final Report. The New England Journal of Medicine. 2020 Oct 8;338(19):1813-26.
Wang Y, Zhang D, Du G, Du R, Zhao J, Jin Y, Fu S, Gao L, Cheng Z, Lu Q, Hu Y. Remdesivir in adults with severe COVID-19: a randomized, double-blind, placebo-controlled, multicentre trial. The Lancet. 2020 Apr 29.
Stone JH, Frigault MJ, Serling-Boyd NJ, Fernandes AD, Harvey L, Foulkes AS, Horick NK, Healy BC, Shah R, Bensaci AM, Woolley AE. Efficacy of tocilizumab in patients hospitalized with Covid-19. New England Journal of Medicine. 2020 Dec 10;383(24):2333-44.
Kewan T, Covut F, Al–Jaghbeer MJ, Rose L, Gopalakrishna KV, Akbik B. Tocilizumab for treatment of patients with severe COVID–19: A retrospective cohort study. EClinicalMedicine. 2020 Jul 1;24:100418.
King CS, Sahjwani D, Brown AW, Feroz S, Cameron P, Osborn E, Desai M, Djurkovic S, Kasarabada A, Hinerman R, Lantry J. Outcomes of mechanically ventilated patients with COVID-19 associated respiratory failure. Plos one. 2020 Nov 23;15(11):e0242651.